title: Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients.
abstract: OBJECTIVE
  In renal allograft recipients, trimetazidine (Vastarel) was proposed to be associated with the classic immunosuppressant treatments because it displays anti-ischaemic effects which may protect against cyclosporine A nephrotoxicity. The objective of this work was to assess the possibility of coadministering cyclosporin A, Sandimmun, and trimetazidine.
  
  
  METHODS
  Twelve renal transplant patients were selected on the basis of the stability of their cyclosporine A blood concentrations for the previous 3 months. They received trimetazidine, 40 mg twice daily orally for 5 days. Other coadministered drugs were kept unchanged during the study. Before and after trimetazidine administration, cyclosporine A blood concentrations, plasma interleukin-2 and soluble interleukin-2 receptor levels were measured.
  
  
  RESULTS
  The data showed that neither cyclosporin A blood pharmacokinetic parameters, Cmax, tmax, AUC, nor the concentrations of interleukin-2 and soluble interleukin-2 receptors were significantly modified.
  
  
  CONCLUSIONS
  Therefore, it was suggested that trimetazidine may be coadministered with cyclosporine A without cyclosporine A dosage adjustment.
authors.affiliation: Service Hospitalo-Universitaire de Néphrologie, Hôpital Sainte Marguerite, Marseille, France.
authors.forename: N
authors.initials: N
authors.lastname: Simon
authors.forename: P
authors.initials: P
authors.lastname: Brunet
authors.forename: D
authors.initials: D
authors.lastname: Roumenov
authors.forename: B
authors.initials: B
authors.lastname: Dussol
authors.forename: J
authors.initials: J
authors.lastname: Barre
authors.forename: J C
authors.initials: JC
authors.lastname: Duche
authors.forename: E
authors.initials: E
authors.lastname: Albengres
authors.forename: P D
authors.initials: PD
authors.lastname: D'Athis
authors.forename: A M
authors.initials: AM
authors.lastname: Chauvet-Monges
authors.forename: Y
authors.initials: Y
authors.lastname: Berland
authors.forename: J P
authors.initials: JP
authors.lastname: Tillement
mesh_terms: D000328:Adult; D000368:Aged; D019540:Area Under Curve; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000097:blood*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood*; D007376:Interleukin-2 / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D014292:Trimetazidine / Q000493:pharmacokinetics*; D014665:Vasodilator Agents / Q000493:pharmacokinetics*
chemical_list: D007166:Immunosuppressive Agents; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D014665:Vasodilator Agents; D016572:Cyclosporine; D003404:Creatinine; D014292:Trimetazidine